Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8<sup>+</sup> T-cell activation.

BMC medicine·2026

Same author

Kyphoscoliotic Ehlers-Danlos syndrome due to a novel homozygous PLOD1 variant: severe vascular involvement and molecular diagnosis.

BMC medical genomics·2026

Same author

Callicarpa nudiflora-derived extracellular vesicle-like particles loaded with budesonide enhance the treatment of ulcerative colitis by regulating M1/M2 macrophage polarization.

Biomaterials advances·2026

Same author

Low-Pass Genome Sequencing Reveals Associations Between Chromosomal Aberrations and Ultrasonographic Anomalies in a Cohort of 19,452 Fetuses.

Prenatal diagnosis·2026

Same author

Precise excision of expanded GGC repeats in NOTCH2NLC via CRISPR/Cas9 for treating neuronal intranuclear inclusion disease.

Nature communications·2026

Same author

Genetic characterization and screening of congenital adrenal hyperplasia by long-read sequencing in a cohort of 21,239 newborns.

Genome medicine·2025

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand.

Shuqing Tang¹, Yusang Zhang¹, Peiyun Wang¹

¹Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.

|April 25, 2025

Summary

Engineered mesenchymal stem cells (iMSCs) show improved tumor targeting. These iMSCs, derived from induced pluripotent stem cells (iPSCs), enhance cancer therapy delivery by better homing to tumors.

Keywords:

Biological sciences Cancer Cancer systems biology Cell biology Molecular biology Natural sciences Systems biology

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Biotechnology
Cancer Research
Stem Cell Therapy

Background:

Mesenchymal stem cells (MSCs) show promise in cancer therapy but suffer from poor tumor homing and heterogeneity.
Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) offer a more homogeneous alternative.
Enhancing iMSC tumor targeting is crucial for effective cancer treatment.

Purpose of the Study:

To develop iMSCs with enhanced tumor targeting capabilities.
To investigate the efficacy of NKG2D-chimeric antigen receptor (CAR) engineering in iMSCs.
To evaluate the in vitro and in vivo homing and binding of engineered iMSCs to tumor cells.

Main Methods:

Generated NKG2D-CAR-iPSCs by targeting the B2M locus in iPSCs.
Differentiated NKG2D-CAR-iPSCs into NKG2D-CAR-iMSCs.
Assessed in vitro migration and adhesion to tumor cells.
Performed RNA sequencing to analyze gene expression changes.
Evaluated tumor homing in an A549 xenograft mouse model.

Main Results:

NKG2D-CAR engineering significantly enhanced iMSC migration and adhesion to tumor cells expressing NKG2D ligands.
RNA-seq revealed upregulation of genes associated with cell adhesion and migration in NKG2D-CAR-iMSCs.
NKG2D-CAR-iMSCs exhibited a 57% improvement in tumor homing compared to unmodified iMSCs in a xenograft model.

Conclusions:

NKG2D-CAR-iMSCs demonstrate superior targeting specificity for tumor cells expressing NKG2D ligands.
This engineered cell therapy shows potential as an off-the-shelf living carrier for targeted anti-cancer drug delivery.
Further investigation into NKG2D-CAR-iMSCs is warranted for advancing cancer therapeutics.